Development PipelineTucatinib

a highly selective small molecule tyrosine kinase inhibitor being investigated in multiple HER2-overexpressed/amplified and HER2-mutated cancers

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

CompassHER2 RD: High-risk adjuvant HER2+ breast cancer (tucatinib or placebo + T-DM1)

ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

HER2CLIMB-02: HER2+ metastatic breast cancer (tucatinib or placebo +T-DM1)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

HER2CLIMB-05: HER2+ metastatic breast cancer maintenance therapy (tucatinib or placebo + trastuzumab + pertuzumab)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

MOUNTAINEER-03: HER2+ metastatic colorectal cancer (tucatinib + trastuzumab + mFOLFOX6 vs mFOLFOX6 ± cetuximab or bevacizumab)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

HER2CLIMB-04: HER2+ metastatic breast cancer (tucatinib + T-DXd)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

MOUNTAINEER: HER2+ metastatic colorectal cancer (tucatinib + trastuzumab)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

MOUNTAINEER-02: HER2+ metastatic gastroesophageal cancer (tucatinib + trastuzumab + ramucirumab + paclitaxel)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGNTUC-019: Metastatic solid tumors driven by HER2 alterations (tucatinib + trastuzumab)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGNTUC-024: HER2+ metastatic gastrointestinal cancers (tucatinib + trastuzumab ± pembrolizumab ± FOLFOX or CAPOX)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of tucatinib and ongoing clinical trials

Detailed information about tucatinib clinical trials

Related Videos

Tucatinib Proposed Mechanism of Action